Acadia Pharmaceuticals | ACAD - Cost Of Sales


Acadia Pharmaceuticals reported $26.22M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 2.54M 2.05M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
J&J USD 7.97B 689M Dec/2025
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025